Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
[{"orgOrder":0,"company":"Psycheceutical","sponsor":"Vici Health Sciences","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"$10.5 million","newsHeadline":"Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"iNGEN\u016b","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect\u2122 Ketamine Topical Cream in Treating PTSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Psycheceutical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            NeuroDirect (ketamine) is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant, for treating PTSD.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: NeuroDirect

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical to treat Post-traumatic stress disorder ​in Australia.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: NeuroDirect™ Ketamine

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: iNGENū

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ketamine is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant. It is being currently developed for PTSD.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Vici is an end-to-end pharmaceutical research and development company specializing in taking projects from pre-clinical research through the Phase 2 stage of FDA approval.

            Lead Product(s): Undisclosed

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: Vici Health Sciences

            Deal Size: $10.5 million Upfront Cash: $10.5 million

            Deal Type: Acquisition August 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY